NPC1 Genotype

If you have a family member with Niemann-Pick disease type C, unexplained liver or spleen enlargement, or adult-onset neurological or psychiatric symptoms that no one has been able to pin down, the NPC1 (Niemann-Pick C1) gene is one of the first places a specialist looks. This test reads the DNA sequence of that gene to find pathogenic variants that, when inherited from both parents, cause a serious cholesterol-handling disorder, and when inherited from one parent, identify you as a carrier.

The result you receive is permanent. Your NPC1 sequence does not change with diet, age, or treatment. What changes is how you act on the information: who in your family gets tested, what conditions you monitor for, and how seriously you take certain symptoms that might otherwise be brushed off.

What This Gene Actually Does

NPC1 encodes a large protein that sits in the membrane of your cells' recycling compartments, called late endosomes and lysosomes. Its job is to move cholesterol and other fats out of those compartments so the rest of the cell can use them. When both copies of the gene carry damaging mutations, cholesterol and certain fatty molecules pile up inside cells, particularly in the liver, spleen, and brain. The disease that results is Niemann-Pick disease type C1 (NPC1), an autosomal recessive condition meaning you need two faulty copies to develop it.

Roughly 95% of Niemann-Pick type C cases come from mutations in NPC1. A second, much rarer form is caused by mutations in a different gene, NPC2, which encodes a partner protein in the same cholesterol-transport pathway. The two genes work together but are distinct genetic causes of the same disease, Niemann-Pick disease type C.

The Variant Landscape Is Enormous

Few genes have as much variation as NPC1. The largest published cohort of 602 patients identified 287 different pathogenic or likely pathogenic variants, including 73 that had never been reported before. Earlier work catalogued 114 NPC1 mutations across 143 patients. An Italian cohort of 105 patients found 84 different NPC1 alleles with 18 novel variants. Current databases now list more than 380 NPC1 mutations, and new ones continue to be added with nearly every published series.

A few variants show up more often than others. The p.I1061T mutation is relatively common among Western Europeans and tracks with the classic juvenile-onset form of the disease. The p.P1007A and p.S954L variants are among the more frequently reported and tend to associate with milder, later-onset presentations. The p.A1035V variant is also frequently reported and has been linked to vertical supranuclear gaze palsy alongside p.I1061T and p.S954L.

Genotype Predicts the Shape of the Disease

If both of your copies are loss-of-function mutations, the kind that completely break the protein, the disease tends to show up earlier, hit harder, and involve more of the body's organs. In the largest NPC1 cohort, biallelic loss-of-function variants linked to earlier age at diagnosis, substantially higher levels of a disease biomarker called PPCS, and prominent liver and spleen involvement. Italian data echoed this: the most severe infantile forms almost always involved two null mutations.

If at least one of your copies carries a missense mutation, where the protein is still made but works imperfectly, the disease often arrives later. Every patient with juvenile or adult-onset disease in the Italian cohort carried at least one missense variant. The specific variants p.P1007A and p.S954L tracked with later diagnosis and only mildly elevated biomarker levels.

A structural model developed across Chinese, Italian, and UK cohorts of NPC1 patients takes this further by looking at where in the protein the mutation lives. Variants on the protein's outer surface usually produce milder disease, partially buried variants produce intermediate disease, and deeply buried variants produce the most severe forms. The model correctly predicted the clinical phenotype for 80% to 93% of patients across the three cohorts.

Carrier Status Is More Common Than People Realize

Analysis of population sequencing data suggests that between 0.56% and 3.26% of people carry one pathogenic NPC1 mutation, with notable differences across ethnic groups. Carrying a single faulty copy does not cause the full disease, but late-onset and milder visceral forms appear to be substantially underdiagnosed. Some common NPC1 variants, including p.H215R, may contribute, in combination with another variant, to subtle adult-onset presentations.

There is also evidence that NPC1 carrier status may influence body weight regulation in the general population, with heterozygous mutations contributing to a meaningful and ethnicity-dependent fraction of obesity risk.

What the Disease Looks Like

Niemann-Pick disease type C1 is one of the most variable inherited disorders in medicine. The age at which the first neurological symptom appears strongly predicts how the disease will progress and how long survival will be. The earlier the neurological onset, the shorter the expected lifespan.

Visceral involvement often comes first. Newborns may show prolonged jaundice, an enlarged liver and spleen, and in the most severe cases, fatal liver failure by six months of age. Neurological symptoms in older children and adults include loss of motor skills, ataxia (loss of coordinated movement), seizures, difficulty swallowing, dystonia (involuntary muscle contractions), a distinctive eye movement abnormality called vertical supranuclear gaze palsy, dementia, and a range of psychiatric symptoms. In adults, the picture can look like a primary psychiatric or movement disorder, which is one reason diagnosis is so often delayed.

Connections Beyond the Classic Disease

Common variation in NPC1 is being studied as a contributor to broader metabolic biology. Loss of NPC1 function in liver cells diverts more carbon into cholesterol synthesis and reduces triglyceride production. In human population studies, the A allele of one common NPC1 variant (rs1429934) tracks with higher serum triglyceride levels across several cohorts. A polymorphism in a separate but related gene, SOAT1 (sterol O-acyltransferase 1), was associated with earlier neurological onset and more severe disease in 117 NPC1 patients, illustrating that other genes can modify how an NPC1 genotype actually plays out.

Other claimed associations have not held up. Common and rare NPC1 variants were specifically tested in 6,304 people and did not show an association with Parkinson's disease. Whether NPC1 variability meaningfully contributes to Alzheimer's-related amyloid pathology remains an open question.

When Results Can Be Misleading

Genetic tests are precise about the variants they look for, but several pitfalls can distort interpretation:

• Panel coverage limits: the test detects only the specific variants its panel is designed to catch. A negative result rules out the variants tested, not every possible variant in NPC1. With more than 380 pathogenic variants identified to date, a comprehensive sequencing approach is usually preferred over a targeted SNP panel.
• Variants of uncertain significance: sequencing may turn up a novel variant whose clinical meaning has not yet been established. Several recent reports document new NPC1 mutations whose effects had to be confirmed through additional cellular or functional testing.
• Ancestry matters: allele frequencies and the spectrum of common variants differ between populations. A variant common in one group may be rare in another, and population-specific data shape how confidently a result can be interpreted.
• Confirmatory testing: an unexpected or atypical finding on a SNP-style panel often warrants confirmation by a different sequencing method before any clinical action is taken.

A One-Time Test With Lifelong Implications

Your NPC1 genotype is set at conception and does not change. There is no value in retesting the same gene year after year. The value of this result is in what you do with it afterward.

If a pathogenic NPC1 variant is identified, the action shifts to companion testing. For a confirmed Niemann-Pick type C diagnosis, that means tracking disease activity through biomarkers like cholestane-triol, lyso-sphingomyelin (lyso-SM-509, also called PPCS), and 7-ketocholesterol, all of which trend with disease severity. Reduced plasma HDL cholesterol is a consistent finding and one of the few standard-lab clues that something is off. For carriers, the action is mostly informational: knowing your status helps guide reproductive decisions and family conversations.

Decision Pathway for an Unexpected Result

Two pathogenic NPC1 variants confirmed in the same person points to Niemann-Pick disease type C1. The next steps are referral to a metabolic specialist familiar with the disease, baseline assessment of liver and spleen size and function, a neurological evaluation, and biomarker testing using the analytes mentioned above to gauge disease activity. Cholestane-triol levels in particular have been shown to track disease progression in a prospective cohort of NPC patients.

A single pathogenic variant identifies you as a carrier. Your biological siblings each have a 50% chance of also being carriers, and your biological children will be obligate carriers if your partner is not a carrier themselves. Partner testing and genetic counseling become the priority before any pregnancy decisions. Because NPC1 carrier status has been linked to subtle changes in lipid metabolism and possibly body weight regulation, attention to standard cardiometabolic markers becomes more important, not less.

A variant of uncertain significance lands in a different category. The result is real, but its clinical meaning is not yet clear. The action here is typically observation, additional functional testing if available, and consultation with a clinical geneticist who can monitor for reclassification as the literature evolves.